In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $152.00. The company's shares closed last Monday at $44.02. According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.3% and a 29.0% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $86.25, an 88.4% upside from current levels. In a report issued on June 10, H.C.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-blueprint-medicines-bpmc?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Blueprint Medicines Charts.